Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients
Treatment-induced cardiac toxicity represents an important issue in non-small cell lung cancer (NSCLC) patients, and no biomarkers are currently available in clinical practice. A novel and easy-to-calculate marker is the quantitative analysis of calcium plaque in the coronary, calculated on CT. It i...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/3/400 |
| _version_ | 1797624879769452544 |
|---|---|
| author | Valerio Nardone Alfonso Reginelli Giuseppina De Marco Giovanni Natale Vittorio Patanè Marco De Chiara Mauro Buono Gaetano Maria Russo Riccardo Monti Giovanni Balestrucci Maria Salvarezza Gaetano Di Guida Emma D’Ippolito Angelo Sangiovanni Roberta Grassi Ida D’Onofrio Maria Paola Belfiore Giovanni Cimmino Carminia Maria Della Corte Giovanni Vicidomini Alfonso Fiorelli Antonio Gambardella Floriana Morgillo Salvatore Cappabianca |
| author_facet | Valerio Nardone Alfonso Reginelli Giuseppina De Marco Giovanni Natale Vittorio Patanè Marco De Chiara Mauro Buono Gaetano Maria Russo Riccardo Monti Giovanni Balestrucci Maria Salvarezza Gaetano Di Guida Emma D’Ippolito Angelo Sangiovanni Roberta Grassi Ida D’Onofrio Maria Paola Belfiore Giovanni Cimmino Carminia Maria Della Corte Giovanni Vicidomini Alfonso Fiorelli Antonio Gambardella Floriana Morgillo Salvatore Cappabianca |
| author_sort | Valerio Nardone |
| collection | DOAJ |
| description | Treatment-induced cardiac toxicity represents an important issue in non-small cell lung cancer (NSCLC) patients, and no biomarkers are currently available in clinical practice. A novel and easy-to-calculate marker is the quantitative analysis of calcium plaque in the coronary, calculated on CT. It is called the Agatston score (or CAD score). At the same time, other potential predictors include cardiac ultrasonography and anamnesis of the patients. Our work aimed to correlate cardiac biomarkers with overall survival (OS) in NSCLC patients. We retrospectively analyzed patients with NSCLC discussed in the Multidisciplinary Tumor Board of our Institute for the present analysis between January 2018 and July 2022. Inclusion criteria were the availability of basal CT imaging of the thorax, cardiac ultrasonography with the calculation of ejection fraction (EF), and complete anamnesis, including assessment of co-pathologies and pharmacological drugs. The clinical data of the patients were retrospectively collected, and the CAD scores was calculated on a CT scan. All of these parameters were correlated with overall survival (OS) with univariate analysis (Kaplan–Meier analysis) and multivariate analysis (Cox regression analysis). Following the above-mentioned inclusion criteria, 173 patients were included in the present analysis. Of those, 120 patients died in the follow-up period (69.6%), and the median overall survival (OS) was 28 months (mean 47.2 months, 95% CI, 36–57 months). In univariate analysis, several parameters that significantly correlated with lower OS were the stage (<i>p</i> < 0.001), the CAD grading (<i>p</i> < 0.001), history of ischemic heart disease (<i>p</i>: 0.034), use of beta blocker drugs (<i>p</i>: 0.036), and cardiac ejection fraction (<i>p</i>: 0.005). In multivariate analysis, the only parameters that remained significant were as follows: CAD score (<i>p</i>: 0.014, OR 1.56, 95% CI: 1.04–1.83), stage (<i>p</i>: 0.016, OR: 1.26, 95% CI: 1.05–1.53), and cardiac ejection fraction (<i>p</i>: 0.011, OR 0.46, 95% CI: 0.25–0.84). Both CAD score and ejection fraction are correlated with survival in NSCLC patients at all stages of the disease. Independently from the treatment choice, a cardiological evaluation is mandatory for patients with NSCLC. |
| first_indexed | 2024-03-11T09:48:58Z |
| format | Article |
| id | doaj.art-48fc54d0d5fd4447a0a9ff2091542f38 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-11T09:48:58Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-48fc54d0d5fd4447a0a9ff2091542f382023-11-16T16:24:11ZengMDPI AGDiagnostics2075-44182023-01-0113340010.3390/diagnostics13030400Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer PatientsValerio Nardone0Alfonso Reginelli1Giuseppina De Marco2Giovanni Natale3Vittorio Patanè4Marco De Chiara5Mauro Buono6Gaetano Maria Russo7Riccardo Monti8Giovanni Balestrucci9Maria Salvarezza10Gaetano Di Guida11Emma D’Ippolito12Angelo Sangiovanni13Roberta Grassi14Ida D’Onofrio15Maria Paola Belfiore16Giovanni Cimmino17Carminia Maria Della Corte18Giovanni Vicidomini19Alfonso Fiorelli20Antonio Gambardella21Floriana Morgillo22Salvatore Cappabianca23Department of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Translational Medical Science, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Translational Medical Science, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Translational Medical Science, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Translational Medical Science, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyTreatment-induced cardiac toxicity represents an important issue in non-small cell lung cancer (NSCLC) patients, and no biomarkers are currently available in clinical practice. A novel and easy-to-calculate marker is the quantitative analysis of calcium plaque in the coronary, calculated on CT. It is called the Agatston score (or CAD score). At the same time, other potential predictors include cardiac ultrasonography and anamnesis of the patients. Our work aimed to correlate cardiac biomarkers with overall survival (OS) in NSCLC patients. We retrospectively analyzed patients with NSCLC discussed in the Multidisciplinary Tumor Board of our Institute for the present analysis between January 2018 and July 2022. Inclusion criteria were the availability of basal CT imaging of the thorax, cardiac ultrasonography with the calculation of ejection fraction (EF), and complete anamnesis, including assessment of co-pathologies and pharmacological drugs. The clinical data of the patients were retrospectively collected, and the CAD scores was calculated on a CT scan. All of these parameters were correlated with overall survival (OS) with univariate analysis (Kaplan–Meier analysis) and multivariate analysis (Cox regression analysis). Following the above-mentioned inclusion criteria, 173 patients were included in the present analysis. Of those, 120 patients died in the follow-up period (69.6%), and the median overall survival (OS) was 28 months (mean 47.2 months, 95% CI, 36–57 months). In univariate analysis, several parameters that significantly correlated with lower OS were the stage (<i>p</i> < 0.001), the CAD grading (<i>p</i> < 0.001), history of ischemic heart disease (<i>p</i>: 0.034), use of beta blocker drugs (<i>p</i>: 0.036), and cardiac ejection fraction (<i>p</i>: 0.005). In multivariate analysis, the only parameters that remained significant were as follows: CAD score (<i>p</i>: 0.014, OR 1.56, 95% CI: 1.04–1.83), stage (<i>p</i>: 0.016, OR: 1.26, 95% CI: 1.05–1.53), and cardiac ejection fraction (<i>p</i>: 0.011, OR 0.46, 95% CI: 0.25–0.84). Both CAD score and ejection fraction are correlated with survival in NSCLC patients at all stages of the disease. Independently from the treatment choice, a cardiological evaluation is mandatory for patients with NSCLC.https://www.mdpi.com/2075-4418/13/3/400heartNSCLCbiomarkerscardio-oncologyradiotherapy |
| spellingShingle | Valerio Nardone Alfonso Reginelli Giuseppina De Marco Giovanni Natale Vittorio Patanè Marco De Chiara Mauro Buono Gaetano Maria Russo Riccardo Monti Giovanni Balestrucci Maria Salvarezza Gaetano Di Guida Emma D’Ippolito Angelo Sangiovanni Roberta Grassi Ida D’Onofrio Maria Paola Belfiore Giovanni Cimmino Carminia Maria Della Corte Giovanni Vicidomini Alfonso Fiorelli Antonio Gambardella Floriana Morgillo Salvatore Cappabianca Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients Diagnostics heart NSCLC biomarkers cardio-oncology radiotherapy |
| title | Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients |
| title_full | Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients |
| title_fullStr | Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients |
| title_full_unstemmed | Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients |
| title_short | Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients |
| title_sort | role of cardiac biomarkers in non small cell lung cancer patients |
| topic | heart NSCLC biomarkers cardio-oncology radiotherapy |
| url | https://www.mdpi.com/2075-4418/13/3/400 |
| work_keys_str_mv | AT valerionardone roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT alfonsoreginelli roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT giuseppinademarco roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT giovanninatale roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT vittoriopatane roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT marcodechiara roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT maurobuono roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT gaetanomariarusso roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT riccardomonti roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT giovannibalestrucci roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT mariasalvarezza roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT gaetanodiguida roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT emmadippolito roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT angelosangiovanni roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT robertagrassi roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT idadonofrio roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT mariapaolabelfiore roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT giovannicimmino roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT carminiamariadellacorte roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT giovannivicidomini roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT alfonsofiorelli roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT antoniogambardella roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT florianamorgillo roleofcardiacbiomarkersinnonsmallcelllungcancerpatients AT salvatorecappabianca roleofcardiacbiomarkersinnonsmallcelllungcancerpatients |